Alpha 2.0
Login Register
» Articles » PMID: 6145942

How Does Bone-marrow Transplantation Cure Leukaemia?

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1984 Jul 7
PMID 6145942
Citations 30
Authors
R P Gale
R E Champlin
Affiliations
Soon will be listed here.
Abstract

Bone-marrow transplantation from an HLA-identical sibling is effective in eradicating leukaemia in most patients with acute myelogenous leukaemia (AML) in first remission. The efficacy is widely assumed to be related to the high doses of drugs and radiation administered before transplantation. Relapse rates in 31 transplants from monozygotic twins were compared with those in 339 transplants from HLA-identical siblings managed with similar chemoradiotherapy. The actuarial relapse rate in the twins was 59% (95% confidence interval +/- 20%) compared with 18 +/- 4% in the non-twin siblings. The high relapse rate in identical twins may be related to the absence of graft-versus-host disease after transplantation. If success depends substantially on the immunotherapeutic effect of allogeneic bone-marrow, only limited benefit can be expected from autotransplantation and intensification chemotherapy for AML.

Citing Articles

HLA-matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML.

Mitsuyoshi T, Arai Y, Kondo T, Kawata T, Hirabayashi S, Tanaka M EJHaem. 2025; 6(1):e21088.

PMID: 39866933 PMC: 11756973. DOI: 10.1002/jha2.1088.

Machine learning evaluation of intensified conditioning on haematopoietic stem cell transplantation in adult acute lymphoblastic leukemia patients.

Jo T, Inoue K, Ueda T, Iwasaki M, Akahoshi Y, Nishiwaki S Commun Med (Lond). 2024; 4(1):247.

PMID: 39587218 PMC: 11589779. DOI: 10.1038/s43856-024-00680-y.

Platelet-Derived Mitochondria Attenuate 5-FU-Induced Injury to Bone-Associated Mesenchymal Stem Cells.

Chen Y, Liu Z, An N, Zhang J, Meng W, Wang W Stem Cells Int. 2023; 2023:7482546.

PMID: 36756493 PMC: 9902133. DOI: 10.1155/2023/7482546.

Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.

Rasor B, Dickerson T, Zhao Q, Elder P, Brammer J, Larkin K Leuk Lymphoma. 2020; 62(4):944-951.

PMID: 33231122 PMC: 8012251. DOI: 10.1080/10428194.2020.1849677.

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.

Reagan J, Fast L, Nevola M, Mantripragada K, Mulder A, Claas F Blood Cancer J. 2015; 5:e371.

PMID: 26636286 PMC: 4735067. DOI: 10.1038/bcj.2015.100.